Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

745 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, Munir T, Lech-Maranda E, Lamanna N, Tam CS, Shah NN, Coombs CC, Ujjani CS, Fakhri B, Cheah CY, Patel MR, Alencar AJ, Cohen JB, Gerson JN, Flinn IW, Ma S, Jagadeesh D, Rhodes JM, Hernandez-Ilizaliturri F, Zinzani PL, Seymour JF, Balbas M, Nair B, Abada P, Wang C, Ruppert AS, Wang D, Tsai DE, Wierda WG, Jurczak W. Mato AR, et al. Among authors: zinzani pl. N Engl J Med. 2023 Jul 6;389(1):33-44. doi: 10.1056/NEJMoa2300696. N Engl J Med. 2023. PMID: 37407001 Clinical Trial.
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Horwitz S, et al. Among authors: zinzani pl. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Lancet. 2019. PMID: 30522922 Free PMC article. Clinical Trial.
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study.
Kuruvilla J, Armand P, Hamadani M, Kline J, Moskowitz CH, Avigan D, Brody JD, Ribrag V, Herrera AF, Morschhauser F, Kanate A, Zinzani PL, Bitran J, Ghesquieres H, Schuster SJ, Farooqui M, Marinello P, Bartlett NL. Kuruvilla J, et al. Among authors: zinzani pl. Leuk Lymphoma. 2023 Jan;64(1):130-139. doi: 10.1080/10428194.2022.2136956. Epub 2022 Nov 18. Leuk Lymphoma. 2023. PMID: 36398795 Clinical Trial.
European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours.
Nanni C, Kobe C, Baeßler B, Baues C, Boellaard R, Borchmann P, Buck A, Buvat I, Chapuy B, Cheson BD, Chrzan R, Cottereau AS, Dührsen U, Eikenes L, Hutchings M, Jurczak W, Kraeber-Bodéré F, Lopci E, Luminari S, MacLennan S, Mikhaeel NG, Nijland M, Rodríguez-Otero P, Treglia G, Withofs N, Zamagni E, Zinzani PL, Zijlstra JM, Herrmann K, Kunikowska J. Nanni C, et al. Among authors: zinzani pl. Lancet Haematol. 2023 May;10(5):e367-e381. doi: 10.1016/S2352-3026(23)00030-3. Lancet Haematol. 2023. PMID: 37142345 Free article. Review.
Copanlisib population pharmacokinetics from phase I-III studies and exposure-response relationships in combination with rituximab.
Morcos PN, Moss J, Austin R, Hiemeyer F, Zinzani PL, Beckert V, Mongay Soler L, Childs BH, Garmann D. Morcos PN, et al. Among authors: zinzani pl. CPT Pharmacometrics Syst Pharmacol. 2023 Nov;12(11):1666-1686. doi: 10.1002/psp4.13000. Epub 2023 Jun 30. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37389853 Free PMC article.
Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity.
De Matteis S, Dicataldo M, Casadei B, Storci G, Laprovitera N, Arpinati M, Maffini E, Cortelli P, Guarino M, Vaglio F, Naddeo M, Sinigaglia B, Zazzeroni L, Guadagnuolo S, Tomassini E, Bertuccio SN, Messelodi D, Ferracin M, Bonafè M, Zinzani PL, Bonifazi F. De Matteis S, et al. Among authors: zinzani pl. Front Immunol. 2023 Jan 16;13:1058126. doi: 10.3389/fimmu.2022.1058126. eCollection 2022. Front Immunol. 2023. PMID: 36726971 Free PMC article.
Real-world clinical effectiveness and safety of CT-P10 in patients with diffuse large B-cell lymphoma: An observational study in Europe.
Bishton MJ, Salles G, Golfier C, Knauf W, Bocchia M, Turner D, Slama B, Harchowal J, Marshall S, Bosi A, Lleonart JJB, Welslau M, Kim S, Lee YN, Zinzani PL, Laribi K. Bishton MJ, et al. Among authors: zinzani pl. EJHaem. 2022 Nov 6;4(1):45-54. doi: 10.1002/jha2.593. eCollection 2023 Feb. EJHaem. 2022. PMID: 36819165 Free PMC article.
Safety of third dose of COVID-19 vaccination in frail patients: Results from the prospective Italian VAX4FRAIL study.
Di Cosimo S, Lupo-Stanghellini MT, Costantini M, Mantegazza R, Ciceri F, Salvarani C, Zinzani PL, Mantovani A, Ciliberto G, Uccelli A, Baldanti F, Apolone G, Delcuratolo S, Morrone A, Locatelli F, Agrati C, Silvestris N. Di Cosimo S, et al. Among authors: zinzani pl. Front Oncol. 2022 Oct 20;12:1002168. doi: 10.3389/fonc.2022.1002168. eCollection 2022. Front Oncol. 2022. PMID: 36338743 Free PMC article.
Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy.
De Matteis S, Casadei B, Lolli G, Dicataldo M, Barbato F, Dan E, Paccagnella A, Sinigaglia B, Bertuzzi C, Arcari A, Zazzeroni L, Bernuzzi P, Laprovitera N, Storci G, Bertuccio SN, Ferracin M, Bonafè M, Zinzani PL, Bonifazi F. De Matteis S, et al. Among authors: zinzani pl. Front Immunol. 2022 Oct 6;13:994731. doi: 10.3389/fimmu.2022.994731. eCollection 2022. Front Immunol. 2022. PMID: 36275688 Free PMC article.
745 results